Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies

mAbs

Volumn 6, Issue 4, 2014, Pages 978-990

  Fu, Wenyan ^a,b   Wang, Yuxiao ^a   Zhang, Yunshan ^a   Xiong, Lijuan ^a   Takeda, Hiroaki ^c   Ding, Li ^a   Xu, Qunfang ^d   He, Lidong ^a   Tan, Wenlong ^e   Bethune, Augus N ^c   Zhou, Lijun ^a  

^a NAVY GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Department of Biochemistry Norman Institute for Cancer Research   (Canada)

^d BEIJING ELECTRIC POWER HOSPITAL   (China)

^e BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Breast cancer; Crystal structure; HER2; Transmembrane signal transduction; Trastuzumab resistance

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F0178 C1; MONOCLONAL ANTIBODY F0179; MONOCLONAL ANTIBODY F0179 C1; MONOCLONAL ANTIBODY FAB37; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; CANCER ANTIBODY; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY ISOLATION; ANTIBODY STRUCTURE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CONTROLLED STUDY; CRYSTALLOGRAPHY; DIMERIZATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; INHIBITION KINETICS; LIGAND BINDING; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84903720923     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28786     Document Type: Article

References (50)

1. Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4(Suppl 2):S70-5; PMID:14667277; http://dx.doi.org/10. 3816/CBC.2003.s.018
2. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808; PMID:9797688; http://dx.doi.org/10.1016/S0959-8049(97)10157-5
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/ 10.1126/science.3798106
4. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001; 7:171-7; PMID:11692142; http://dx.doi.org/10.1007/BF03032345
5. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl 4):S3-8; PMID:11597398; http://dx.doi.org/10.1016/S0959-8049(01)00230-1
6. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-16; PMID:16829981; http://dx.doi.org/10.1038/ nrm1962
7. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006; 16:649-56; PMID:17085050; http://dx.doi.org/10. 1016/j.tcb.2006.10.008
8. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology 2002; 63(Suppl 1):17-24; PMID:12422051; http://dx.doi.org/10.1159/ 000066203
9. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance in breast cancer cells. Cytometry A 2004; 57:86-93; PMID:14750129; http://dx.doi.org/10.1002/ cyto.a.10095
10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535- 6108(04)00083-2
11. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/10.1016/S1535-6108(02)00097-1
12. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10. 1038/nature01392
13. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40; PMID:19411071; http://dx.doi.org/10.1016/ j.ccr.2009.03.020
14. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends J-W, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
15. Wang YX, Jia PY, Wang YX, Qiao YY, Yang RF, Zhou LJ. [Cloning of human scFv against soman transition state analogues (P6) from a large phage antibody library]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010; 26:250-2; PMID:20230690
16. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 2013; 288:27059-67; PMID:23943614; http://dx.doi.org/10.1074/ jbc.M113.491530
17. Fisher RD, Ultsch M, Lingel A, Schaefer G, Shao L, Birtalan S, Sidhu SS, Eigenbrot C. Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol 2010; 402:217-29; PMID:20654626; http://dx.doi.org/10.1016/j.jmb.2010.07.027
18. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 2013; 288:27059-67; PMID:23943614; http://dx.doi.org/10.1074/ jbc.M113.491530
19. Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-9; PMID:21060033; http://dx.doi.org/10.1200/JCO.2010.29.7101
20. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-andshut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-52; PMID:14527402; http://dx.doi.org/10.1016/S1097-2765(03)00350-2
21. Alvarado D, Klein DE, Lemmon MA. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 2010; 142:568-79; PMID:20723758; http://dx.doi.org/10.1016/j.cell.2010.07.015
22. Alvarado D, Klein DE, Lemmon MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 2009; 461:287-91; PMID:19718021; http://dx.doi.org/10.1038/nature08297
23. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-48; PMID:9367782; http://dx.doi.org/10.1006/jmbi.1997.1354
24. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656
25. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19:124-34; PMID:17314037; http://dx.doi.org/10.1016/j.ceb.2007.02.008
26. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
27. Silva F, Cisternas M, Specks U. TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis. Curr Rheumatol Rep 2012; 14:501-8; PMID:22956157; http://dx.doi.org/10.1007/s11926-012-0290-2
28. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11:495-505; PMID:12620236; http://dx.doi.org/10. 1016/S1097-2765(03)00048-0
29. Horan T, Wen J, Arakawa T, Liu N, Brankow D, Hu S, Ratzkin B, Philo JS. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem 1995; 270:24604-8; PMID:7592681; http://dx.doi.org/10.1074/ jbc.270.41.24604
30. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988; 8:5570-4; PMID:2907606
31. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. J Biol Chem 1995; 270:3068-73; PMID:7531698
32. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem 2002; 277:28468-73; PMID:12000754; http://dx.doi.org/ 10.1074/jbc.M202510200
33. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323-32; PMID:17636564; http://dx.doi.org/10.1002/ibd.20225
34. Miura GI, Buglino J, Alvarado D, Lemmon MA, Resh MD, Treisman JE. Palmitoylation of the EGFR ligand Spitz by Rasp increases Spitz activity by restricting its diffusion. Dev Cell 2006; 10:167-76; PMID:16459296; http://dx.doi.org/10.1016/j.devcel.2005.11.017
35. Sliwkowski MX. Pari passu dimers of dimers. Proc Natl Acad Sci U S A 2012; 109:13140-1; PMID:22851769; http://dx.doi.org/10.1073/pnas.1209959109
36. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008; 68:2400-8; PMID:18381448; http://dx.doi.org/10.1158/0008-5472.CAN-07-6663
37. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-14; PMID:9630891; http://dx.doi.org/10. 1038/nbt0396-309
38. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992; 226:889-96; PMID:1507232; http://dx.doi.org/10.1016/0022-2836(92)90639-2
39. He M, Menges M, Groves MA, Corps E, Liu H, Brüggemann M, Taussig MJ. Selection of a human anti-progesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J Immunol Methods 1999; 231:105-17; PMID:10648931; http://dx.doi.org/10.1016/S0022-1759(99)00144-1
40. Hudziak RM, Ullrich A. Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. J Biol Chem 1991; 266:24109-15; PMID:1684181
41. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
42. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. CW, Sweet RM, eds. Macromolecular Crystallography, part A: Academic Press, 1997:307-26. (Pubitemid 27085611)
43. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 2005; 61:458-64; PMID:15805601; http://dx.doi.org/10.1107/S0907444905001617
44. Matthews BW. Solvent content of protein crystals. J Mol Biol 1968; 33:491-7; PMID:5700707; http://dx.doi.org/10.1016/0022-2836(68)90205-2
45. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-32; PMID:15572765; http://dx.doi.org/10.1107/S0907444904019158
46. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58:1948-54; PMID:12393927; http://dx.doi.org/10.1107/S0907444902016657
47. Laskowski R, MacArthur M, Moss D, Thornton J. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26:283-91; http://dx.doi.org/10.1107/S0021889892009944
48. DeLano W. The PyMOL Molecular Graphics System 2002
49. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999; 19:6845-57; PMID:10490623
50. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171:1918-26; PMID:1290249